Can Kidney Problems Complicate Interpretation of Alzheimer’s Blood Biomarkers?

Learn how kidney function shifts Alzheimer's blood tests and what to check before trusting a positive result.

Yes. Kidney problems can raise Alzheimer's blood test results even when brain changes are absent.

Alzheimer's blood biomarkers are proteins in blood, such as p-tau and neurofilament light, that help signal Alzheimer's-related brain change. Kidney filtering is measured by eGFR, or estimated glomerular filtration rate. When eGFR falls, the kidneys clear less protein from blood, so biomarker levels can look worse than the brain truly is.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

How does kidney function change biomarker levels?

Chronic kidney disease raises circulating Alzheimer's blood biomarkers independently of brain pathology. According to the Alzheimer's Research & Therapy review, lower kidney function is linked to higher p-tau217, p-tau181, GFAP and NfL and a lower Aβ42/40 ratio. The pattern is nonlinear.

Lower eGFR is associated with higher p-tau181, p-tau217, total tau, NfL and GFAP, with the strongest effect for NfL. NfL marks nerve injury, GFAP marks brain immune activation, and p-tau forms track tau buildup. At very low kidney function, the shifts are large enough to matter. At eGFR 30, median increases were about 0.20-0.24 standard deviations for p-tau181, p-tau217 and total tau, 0.88 for NfL and 0.10 for GFAP, while Aβ42/40 changed little, as reported by Drugs.com covering the Swedish aging study.

Who is most likely to be affected?

Older adults with eGFR below 60 face the greatest uncertainty, especially those with moderate-to-severe chronic kidney disease. Reduced renal clearance can elevate tau, amyloid-β40, NfL and GFAP without added dementia risk. That matters because both kidney decline and memory concerns rise with age.

A person evaluated for mild cognitive impairment may already have long-standing hypertension, diabetes, heart disease or medication-related kidney strain. The overlap makes context essential. A mildly high p-tau in someone with stable mild kidney decline may mean something different than the same value in someone with healthy kidneys.

Can poor kidney function cause a false positive?

Yes, it can push a screening result across the cutoff. About half of people with eGFR 35 had p-tau levels above the positivity cutoff in research presented at AAIC 2024, according to Mayo Clinic research reported by AlzForum. CKD or stroke history also raised p-tau181 and p-tau217. This does not mean the test is useless in kidney disease.

It means a single cutoff can misclassify people when clearance is poor, particularly for borderline-positive results. There is also an important limit to simple correction. Adding eGFR to models with plasma biomarkers, age and sex did not meaningfully improve prediction of amyloid-PET positivity or discrimination. Kidney information helps interpretation, but adjustment alone does not resolve diagnosis.

What should you do before acting on a result?

Ask the clinician to review kidney function alongside the biomarker result. Current clinical guidance emphasizes checking eGFR when interpreting results, favoring ratio or percentage measures such as %p-tau217 that are less kidney-sensitive, and confirming borderline positives with amyloid PET or spinal-fluid testing when major comorbidity exists, according to JAMA Neurology clinical guidance.

Bring these items to the visit: Do not change dementia medicines, driving, work, advance planning or trial enrollment from one blood result alone. Use the result as a prompt for specialist review, repeat testing when illness resolves, and confirmation when treatment or major life decisions depend on it.

  • Recent eGFR and creatinine results, plus whether kidney function is stable, improving or worsening
  • Full medication and supplement list, hydration status, recent illness, hospitalization or contrast procedures
  • Heart, stroke, diabetes and blood-pressure history, since vascular disease can also affect markers
  • The exact test name, cutoff used, and whether a repeat blood draw or PET or spinal-fluid confirmation is appropriate

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.